199 related articles for article (PubMed ID: 15317405)
1. Pharmacoeconomics of thrombosis management.
Hawkins D
Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
[TBL] [Abstract][Full Text] [Related]
2. Economic considerations in the prevention and treatment of venous thromboembolism.
Hawkins D
Am J Health Syst Pharm; 2004 Dec; 61(23 Suppl 7):S18-21. PubMed ID: 15597575
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
4. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
5. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.
Nutescu EA
Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S5-13. PubMed ID: 17519445
[TBL] [Abstract][Full Text] [Related]
6. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
Reynolds NA; Perry CM; Scott LJ
Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
[TBL] [Abstract][Full Text] [Related]
9. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
Nijkeuter M; Huisman MV
Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Spruill WJ; Wade WE; Leslie RB
Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
[TBL] [Abstract][Full Text] [Related]
12. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness analysis of enoxaparin for the prophylaxis of venous thromboembolism in major orthopedic surgery patients].
Brosa Riestra M; Rubio-Terrés C; Nadipelli V; Casado Collado A; Martínez Brotons F
Farm Hosp; 2003; 27(4):210-8. PubMed ID: 12966450
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
16. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.
Sullivan SD; Kahn SR; Davidson BL; Borris L; Bossuyt P; Raskob G
Pharmacoeconomics; 2003; 21(7):477-96. PubMed ID: 12696988
[TBL] [Abstract][Full Text] [Related]
17. The pharmacoeconomics of deep vein thrombosis treatment.
Shorr AF
Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Shorr AF; Kwong LM; Sarnes M; Happe L; Farrelly E; Mody-Patel N
Thromb Res; 2007; 121(1):17-24. PubMed ID: 17449088
[TBL] [Abstract][Full Text] [Related]
19. Evidence for extended prophylaxis in the setting of orthopedic surgery.
Dobesh PP
Pharmacotherapy; 2004 Jul; 24(7 Pt 2):73S-81S. PubMed ID: 15317402
[TBL] [Abstract][Full Text] [Related]
20. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
Turpie AG
Int J Clin Pract; 2004 May; 58(5):483-93. PubMed ID: 15206506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
